AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33847780 — intervention group
Group type: COMPARATOR
Intervention: Double-J insertion for 3-5 days after ureterorenoscopy
Number of subjects: 108
Study 33847780 — intervention group
Group type: COMPARATOR
Intervention: Tubeless procedure
Number of subjects: 108
Study 34711445 — intervention group
Group type: EXPERIMENTAL
Intervention: Portioning information strategy (pauses during information provision)
Number of subjects: 34
Study 34711445 — intervention group
Group type: COMPARATOR
Intervention: Non-portioning pauses
Number of subjects: 34
Study 34965950 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of aromatase inhibitors (AI)
Number of subjects: 264
Study 34965950 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-term neoadjuvant AI (NeoAI)
Number of subjects: 264
Study 34965950 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (Control)
Number of subjects: 264
Study 32471908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (20 μg subcutaneously daily)
Number of subjects: 30
Study 32471908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35841410 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM + ERL (ramucirumab 10 mg/kg every 2 weeks with erlotinib 150 mg/day)
Number of subjects: 441
Study 35841410 — intervention group
Group type: COMPARATOR
Intervention: PBO + ERL (placebo with erlotinib 150 mg/day)
Number of subjects: 441
Study 33763789 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (group A1)
Number of subjects: 99
Study 33763789 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin plus carboplatin (group A2)
Number of subjects: 99
Study 33763789 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin plus cyclophosphamide (group B1)
Number of subjects: 99
Study 33763789 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin plus capecitabine (group B2)
Number of subjects: 99
Study 32696226 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ESP block with ropivacaine
Number of subjects: 82
Study 32696226 — intervention group
Group type: COMPARATOR
Intervention: Continuous ESP block with 0.9% saline (saline group)
Number of subjects: 82
Study 36127862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education programme based on the health belief model (8 sessions over 15 days)
Number of subjects: 149
Study 36127862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tele-education)
Number of subjects: 149
Study 36127862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education programme based on the health belief model
Number of subjects: 149
Study 32926893 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex quantitative real‐time polymerase chain reaction (mqPCR) assay for PCV2 genotypes
Number of subjects: 0
Study 35378137 — intervention group
Group type: EXPERIMENTAL
Intervention: Archetype 1 (normal VF pattern)
Number of subjects: 165
Study 35378137 — intervention group
Group type: EXPERIMENTAL
Intervention: Global score of AT change
Number of subjects: 165
Study 35378137 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AT2 (mild diffuse VF loss pattern) weight of 44% or more
Number of subjects: 165
Study 35378137 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide treatment
Number of subjects: 165
Study 35378137 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual VF loss patterns
Number of subjects: 165
Study 33429768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/d for 10 days, 20 days free of treatment, repeated for 3 courses over 3 months
Number of subjects: 86
Study 33429768 — intervention group
Group type: COMPARATOR
Intervention: Control group (antispasmodics as needed, observed for 3 months)
Number of subjects: 86
Study 32470230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (30-70 mg)
Number of subjects: 0
Study 32470230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33970692 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complex decongestive therapy (CDT) started within 2 weeks after surgery for 30 minutes a day, for 2 weeks (5 days per week)
Number of subjects: 31
Study 33970692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 31
Study 33970692 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complex decongestive therapy (CDT)
Number of subjects: 31
Study 33867262 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 40
Study 33867262 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 35298858 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing pseudo-ceramide and eucalyptus extract
Number of subjects: 19
Study 35298858 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer without pseudo-ceramide and eucalyptus extract
Number of subjects: 19
Study 32330433 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1mg/kg/day for 24 weeks, tapering from week 9)
Number of subjects: 38
Study 32330433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32195959 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with tamsulosin hydrochloride sustained-release capsule
Number of subjects: 166
Study 32195959 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment (control)
Number of subjects: 166
Study 35152055 — intervention group
Group type: EXPERIMENTAL
Intervention: External representation (computer)
Number of subjects: 0
Study 35152055 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal representation (mental)
Number of subjects: 0
Study 35152055 — intervention group
Group type: EXPERIMENTAL
Intervention: First solving a problem mentally
Number of subjects: 0
Study 34836280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative protein caloric restriction (PCR) diet (30% calorie, 70% protein restriction) for four days
Number of subjects: 19
Study 34836280 — intervention group
Group type: COMPARATOR
Intervention: Regular ad-libitum diet
Number of subjects: 19
Study 32517654 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO) during endurance training
Number of subjects: 0
Study 32517654 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) without protein supplementation
Number of subjects: 0
Study 34274496 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy based on CYP2C19 genotype and urine 11‐dhTxB2 tests
Number of subjects: 0
Study 34274496 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 34553654 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 32
Study 34621052 — intervention group
Group type: EXPERIMENTAL
Intervention: Aramchol 600 mg
Number of subjects: 247
Study 34621052 — intervention group
Group type: EXPERIMENTAL
Intervention: Aramchol 400 mg
Number of subjects: 247
Study 34621052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 32841941 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin dosing regimens (100 mg/kg q12, 60/30 mg/kg q12/8, 50 mg/kg q12/8/6, 50 mg/kg q12/8/4)
Number of subjects: 0
Study 32841941 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin dosing regimens
Number of subjects: 0
Study 34162239 — intervention group
Group type: EXPERIMENTAL
Intervention: Black older adult cancer survivors
Number of subjects: 321
Study 34162239 — intervention group
Group type: COMPARATOR
Intervention: White older adult cancer survivors
Number of subjects: 321
Study 34162239 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional difficulties (for both groups)
Number of subjects: 321
Study 34162239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-related factors (for Black survivors)
Number of subjects: 321
Study 34091741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck and supramontanal sparing ejaculatory preserving transurethral bipolar resection of prostate (ep‐TUBRP)
Number of subjects: 60
Study 34091741 — intervention group
Group type: COMPARATOR
Intervention: Classic transurethral bipolar resection of prostate (c‐TUBRP)
Number of subjects: 60
Study 35961662 — intervention group
Group type: EXPERIMENTAL
Intervention: Permacol (cross-linked)
Number of subjects: 94
Study 35961662 — intervention group
Group type: COMPARATOR
Intervention: Strattice (not cross-linked)
Number of subjects: 94
Study 33721059 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (three different modalities)
Number of subjects: 128
Study 33721059 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 128
Study 32622626 — intervention group
Group type: EXPERIMENTAL
Intervention: NURD score
Number of subjects: 382
Study 32622626 — intervention group
Group type: EXPERIMENTAL
Intervention: NURD score (adjusted for case-mix differences)
Number of subjects: 382
Study 36199064 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin combined with dulaglutide (MET-DUL group)
Number of subjects: 60
Study 36199064 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy (MET group)
Number of subjects: 60
Study 33449519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-adaptation diet
Number of subjects: 9
Study 33449519 — intervention group
Group type: COMPARATOR
Intervention: Balanced carbohydrate diet
Number of subjects: 9
Study 32060972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/6 of total daily dose
Number of subjects: 85
Study 32060972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/8 of total daily dose
Number of subjects: 85
Study 32060972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/12 of total daily dose
Number of subjects: 85
Study 32060972 — intervention group
Group type: COMPARATOR
Intervention: Control (usual breakthrough dose)
Number of subjects: 85
Study 35701548 — intervention group
Group type: EXPERIMENTAL
Intervention: 94% ABV alcohol (males: 1.0 ml/kg; females: 0.85 ml/kg)
Number of subjects: 20
Study 35701548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34199913 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative telerehabilitation (PT) program
Number of subjects: 60
Study 32168305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia plus melatonin
Number of subjects: 25
Study 32168305 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia plus placebo
Number of subjects: 25
Study 36348358 — intervention group
Group type: EXPERIMENTAL
Intervention: MBC2 diet and activity intervention
Number of subjects: 350
Study 36348358 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (stress and sleep management)
Number of subjects: 350
Study 34232171 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR training (n=10)
Number of subjects: 19
Study 34232171 — intervention group
Group type: COMPARATOR
Intervention: No further training (control group, n=9)
Number of subjects: 19
Study 32727577 — intervention group
Group type: EXPERIMENTAL
Intervention: esaxerenone 2.5 mg with amlodipine 10 mg/day (Study 1)
Number of subjects: 64
Study 32727577 — intervention group
Group type: EXPERIMENTAL
Intervention: esaxerenone 5 mg/day with amlodipine 2.5 mg (Study 2)
Number of subjects: 64
Study 32727577 — intervention group
Group type: EXPERIMENTAL
Intervention: esaxerenone 5 mg/day with digoxin 0.25 mg/day (Study 3)
Number of subjects: 64
Study 36072776 — intervention group
Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 120
Study 36072776 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone combined with Vitamin B6
Number of subjects: 120
Study 33837943 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of landfill leachate (LL) dose plus irrigation water (IW)
Number of subjects: 5
Study 33837943 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% of landfill leachate (LL) dose plus irrigation water (IW)
Number of subjects: 5
Study 33837943 — intervention group
Group type: COMPARATOR
Intervention: 0% of landfill leachate (LL) dose plus irrigation water (IW)
Number of subjects: 5
Study 33837943 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of landfill leachate (LL) dose plus irrigation water (IW)
Number of subjects: 5
Study 33837943 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% of landfill leachate (LL) dose plus irrigation water (IW)
Number of subjects: 5
Study 36232203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training (PT)
Number of subjects: 51
Study 36232203 — intervention group
Group type: COMPARATOR
Intervention: Balance training (BT)
Number of subjects: 51
Study 32621487 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anemia
Number of subjects: 570
Study 32621487 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia of chronic diseases (ACD)
Number of subjects: 570
Study 32621487 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 570
Study 32621487 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated iron
Number of subjects: 570
Study 32621487 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anemia and elevated iron concentrations
Number of subjects: 570
Study 36087576 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning loaded calorie intake (45%:35%:20% calories at breakfast, lunch, and dinner)
Number of subjects: 30
Study 36087576 — intervention group
Group type: COMPARATOR
Intervention: Evening loaded calorie intake (20%:35%:45% calories at breakfast, lunch, and dinner)
Number of subjects: 30
Study 35590308 — intervention group
Group type: COMPARATOR
Intervention: LIA (Local Infiltration Analgesia) with ropivacaine, morphine, and betamethasone
Number of subjects: 60
Study 35590308 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB (Adductor Canal Block) combined with LIA (Local Infiltration Analgesia) with ropivacaine, morphine, and betamethasone
Number of subjects: 60
Study 33478465 — intervention group
Group type: COMPARATOR
Intervention: Financial Incentive (FI) group
Number of subjects: 39
Study 33478465 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Network Incentive plus Financial Incentive (SNI + FI) group
Number of subjects: 39
Study 33172547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia group
Number of subjects: 258
Study 33172547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 258
Study 35172872 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife fistulotomy (NKF)
Number of subjects: 538
Study 35172872 — intervention group
Group type: COMPARATOR
Intervention: Standard cannulation
Number of subjects: 538
Study 34372930 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative intervention comprising risk communication using an online risk calculator, counselling style adapted from motivational interviewing, and 12 weekly telephone goal reinforcement calls (3 months)
Number of subjects: 100
Study 34372930 — intervention group
Group type: COMPARATOR
Intervention: Verbal lifestyle advice only
Number of subjects: 100
Study 32563847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher average proportion days alcohol abstinent
Number of subjects: 313
Study 32563847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher average heavy drinking
Number of subjects: 313
Study 32563847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD)
Number of subjects: 313
Study 32563847 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-specific increases in proportion days alcohol abstinent
Number of subjects: 313
Study 32563847 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-specific increases in AUD
Number of subjects: 313
Study 32563847 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 313
Study 34872927 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-week language therapy
Number of subjects: 68
Study 33393711 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 2.5 g EP/kg diet
Number of subjects: 320
Study 33393711 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 5.0 g EP/kg diet
Number of subjects: 320
Study 33393711 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 7.5 g EP/kg diet
Number of subjects: 320
Study 33393711 — intervention group
Group type: COMPARATOR
Intervention: Basal diet without supplementation (control)
Number of subjects: 320
Study 35093512 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking meditation (WM)
Number of subjects: 32
Study 35093512 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber-band exercise (RE)
Number of subjects: 32
Study 35093512 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 35131532 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycarbophil vaginal (PCV) gel 1 g twice a week for 30 days
Number of subjects: 53
Study 35131532 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) vaginal gel 3 g every 3 days for 30 days
Number of subjects: 53
Study 35131532 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycarbophil vaginal (PCV) gel
Number of subjects: 53
Study 35131532 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) vaginal gel
Number of subjects: 53
Study 35010599 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication
Number of subjects: 1802
Study 35010599 — intervention group
Group type: COMPARATOR
Intervention: No risk communication (Control)
Number of subjects: 1802
Study 36335780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 32
Study 33652160 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal isosorbide mononitrate (40 mg, up to 3 doses)
Number of subjects: 176
Study 33652160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 34913787 — intervention group
Group type: EXPERIMENTAL
Intervention: LY01008
Number of subjects: 112
Study 34913787 — intervention group
Group type: COMPARATOR
Intervention: Avastin®
Number of subjects: 112
Study 33136314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention on healthy lifestyles, education on self-esteem, pain awareness, communication, and relaxation techniques
Number of subjects: 279
Study 33136314 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study 32034481 — intervention group
Group type: COMPARATOR
Intervention: Catheter-based renal denervation
Number of subjects: 300
Study 36074385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 μg/kg/h)
Number of subjects: 327
Study 36074385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 34101342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort implants (5.5 mm)
Number of subjects: 48
Study 34101342 — intervention group
Group type: COMPARATOR
Intervention: Standard-length implants (10 mm)
Number of subjects: 48
Study 33174614 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based pain coping skills training (PCST)
Number of subjects: 107
Study 33174614 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 107
Study 32253688 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRF/ICG
Number of subjects: 196
Study 32253688 — intervention group
Group type: COMPARATOR
Intervention: no-NIRF/ICG
Number of subjects: 196
Study 33160908 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 70
Study 33160908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus oxycodone
Number of subjects: 70
Study 32451777 — intervention group
Group type: EXPERIMENTAL
Intervention: Basivertebral nerve (BVN) ablation
Number of subjects: 117
Study 35758258 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986120 75 mg
Number of subjects: 88
Study 35758258 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986120 180 mg
Number of subjects: 88
Study 35758258 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986120 ≥10 mg for 7 days
Number of subjects: 88
Study 35758258 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986120 (various doses)
Number of subjects: 88
Study 35758258 — intervention group
Group type: COMPARATOR
Intervention: BMS-986120
Number of subjects: 88
Study 34408488 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Number of subjects: 242
Study 34408488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 32422769 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicability sequence entropy and Jensen-Shannon divergence measure
Number of subjects: 0
Study 32422769 — intervention group
Group type: EXPERIMENTAL
Intervention: Real networks
Number of subjects: 0
Study 32422769 — intervention group
Group type: COMPARATOR
Intervention: Randomized network models
Number of subjects: 0
Study 35502036 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricated eyelid speculum
Number of subjects: 130
Study 35502036 — intervention group
Group type: COMPARATOR
Intervention: Dry eyelid speculum
Number of subjects: 130
Study 32794071 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group eHealth interventions
Number of subjects: 57
Study 35554022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on significant indices (age, tumor type, type of surgery, radiation therapy)
Number of subjects: 197
Study 35554022 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and surgical resection
Number of subjects: 197
Study 35554022 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and pathological type
Number of subjects: 197
Study 32449174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (administered every 8 weeks)
Number of subjects: 441
Study 32449174 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (administered every 2 weeks)
Number of subjects: 441
Study 32606085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral small vessel disease (CSVD)
Number of subjects: 1045
Study 32606085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial arterial stenosis (ICAS)
Number of subjects: 1045
Study 32606085 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-point modified CSVD score
Number of subjects: 1045
Study 32606085 — intervention group
Group type: COMPARATOR
Intervention: Control (no CSVD or ICAS)
Number of subjects: 1045
Study 35077197 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analysis of Swallowing Efficiency and Safety (VASES)
Number of subjects: 57
Study 35077197 — intervention group
Group type: COMPARATOR
Intervention: Verbal numerical ratings
Number of subjects: 57